Early and Limited Evidence of Moderna Vaccine Efficacy

As reported in the New York Times, early preliminary results released by Moderna, a Cambridge, MA-based company, suggests that its experimental vaccine is safe and capable of stimulating a robust immune response against SARS-CoV-2.